Rite Aid (RAD) April Comps Rose 5%; Front-End Up 4.7%
Get Alerts RAD Hot Sheet
Join SI Premium – FREE
Rite Aid (NYSE: RAD) announced sales results for April.
Monthly Sales
For the four weeks ended April 26, 2014, same store sales increased 5.0 percent over the prior-year period. April front-end same store sales increased 4.7 percent, with 4.6 percent of the increase attributable to a shift in the timing of Easter, which fell on April 20 this year compared to March 31 last year. Pharmacy same store sales, which included an approximate 138 basis points negative impact from new generic introductions, increased 5.2 percent. Prescription count at comparable stores increased 2.3 percent over the prior-year period.
Total drugstore sales for the four-week period increased 4.9 percent to $1.995 billion compared to $1.902 billion for the same period last year. Prescription sales accounted for 67.9 percent of drugstore sales, and third party prescription sales represented 97.4 percent of pharmacy sales.
Year-to-Date
Same store sales for the eight-week period ended April 26, 2014 increased 2.9 percent over the prior-year period. Front-end same store sales decreased 0.2 percent while pharmacy same store sales increased 4.3 percent. Prescription count at comparable stores increased 1.7 percent over the prior-year period.
Total drugstore sales for the eight weeks ended April 26, 2014 increased 2.6 percent with sales of $3.941 billion compared to $3.841 billion for the same period last year. Prescription sales represented 68.7 percent of total drugstore sales, and third party prescription sales represented 97.4 percent of pharmacy sales.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Radiopharm trial advances to higher dose in HER2+ cancer study
- Alaska Airlines to launch nonstop Seattle flights to Athens and Paris
- Lockheed Martin and Saildrone conduct live-fire USV demo at RIMPAC
Create E-mail Alert Related Categories
Hot Corp. News, Retail SalesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share